Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

A Neva­da start­up re­search­ing an Alzheimer’s drug saw its stock crater Wednes­day morn­ing af­ter it re­port­ed Phase III re­sults that in­clud­ed da­ta in­tegri­ty is­sues at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER